Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 66Lymphoma 35Neutropenia 30Lymphoma, Large B-Cell, Diffuse 23Lymphoma, Non-Hodgkin 18Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 13Hodgkin Disease 13Sarcoma 11Multiple Myeloma 11Lymphoma, Mantle-Cell 10Lymphoma, Follicular 10Leukemia 10Burkitt Lymphoma 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lung Neoplasms 9Triple Negative Breast Neoplasms 8Rhabdomyosarcoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Chemotherapy-induced Neutropenia 7Central Nervous System Neoplasms 6Breast Neoplasms, Male 6Testicular Neoplasms 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lymphoma, B-Cell, Marginal Zone 5Febrile Neutropenia 5Fallopian Tube Neoplasms 5Carcinoma, Ovarian Epithelial 5

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Corpus Sarcoma × pegfilgrastim × Clear all
NCT00031629 2016-12-08

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

GOG Foundation

Phase 2 Completed
51 enrolled
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡